title: Response.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN. Electronic address: limper.andrew@mayo.edu.
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Limper
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000453:epidemiology*; D011020:Pneumonia, Pneumocystis / Q000139:chemically induced* / Q000453:epidemiology*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab